Phage Display‐Derived Antibodies: Application of Recombinant Antibodies for Diagnostics by Ch’ng, Angela Chiew Wen et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
Phage Display‐Derived Antibodies: Application of
Recombinant Antibodies for Diagnostics
Angela Chiew Wen Ch’ng, Yee Siew Choong and
Theam Soon Lim
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63927
Abstract
Antibodies are produced by the human body in response towards infections as a means
of protection. The in vivo production of antibodies by B-cells involves a series of intricate
gene editing processes resulting in a highly diverse pool of antibodies. However, this
diversity  can  be  replicated  in  vitro  using  phage  display.  Phage  display  offers  the
potential to present the antibody phenotype together with the cloned genotype of the
specific antibody in a single-phage particle.  Antibodies are highly sought after for
diagnostic applications owing to its specificity and affinity towards a target antigen.
The advent of recombinant antibody (rAb) technology allows for a faster and more cost-
effective solution for antibody generation. It also provides diagnostic developers with
the possibility to customize the antibodies. Antibodies have been utilized successfully
in various diagnostic platforms ranging from standard immunoassays to lateral-flow
assays, nanoparticles, microfluidics, DNA‐integrated assays and others. The limitless
application of antibodies in the field of diagnostics has made it a critical component in
any diagnostic development platform. This chapter focuses on the processes involved
in antibody discovery including the various forms of  antibody libraries  for  phage
display and panning processes. We also highlight some diagnostic platforms that apply
recombinant antibodies.
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1. Introduction
The human body is made up of a series of complex networks or systems that involve different
tissues and cells to work in harmony to regulate different functions in the human body. The
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
immune system is one of the vital systems in the human body as its main function is to protect
the body from infectious agents and pathogens. The immune system is divided into two main
forms of immunity, namely the innate and acquired immunity. The innate immunity is the
physical barrier that prevents foreign invasion. If the innate immunity fails to inhibit the entrance
of these foreign molecules, the second line of defence being the adaptive immunity will then
come into play. This response will take place with the help of both T‐ and B‐cell [1]. B‐cell
activation to secrete antibodies can work through either the T‐cell dependent or the T‐cell
independent pathway. The T‐cell dependent activation would require T‐helper cells to trigger
the processes required for antibody production through B‐cell proliferation [2]. This will then
lead to the secretion of antibodies in the body.
Over decades, the application and function of antibodies has expanded from being an
immunologically important protein to an essential research tool. The basic application of
antibodies surrounds the natural feature of antibodies being high affinity and specific binders
against target molecules. This feature has allowed antibodies to be successfully applied for
diagnostic and therapeutic applications. In general, diagnostic kits are likely to apply
antibodies with superior affinities and specificity against a target antigen for detection [3] via
different orientations. This includes either the detection of antibodies by antigens, detection
of serum antibodies by the corresponding antigens or by competition [4, 5].
Antibodies are a form of recognition protein [6], which is ubiquitously found in serum and
body fluid of vertebrates. The diverse antibody repertoire is important for the identification
of antibodies against a specific target. Antibodies undergo gene rearrangement processes to
generate different gene segment combinations that result in antibodies with different gene
sequences. The complexity of antibody diversity is mainly attributed to the combinatorial
joining of multiple V, D, J segments of the heavy chain and the V, J segment for the light chain.
This process involves multiple gene‐editing enzymes to produce numerous combinations of
gene segments. After gene segmentation, another process named somatic hypermutation takes
place to further diversify the antibody repertoire [7, 8]. Taken together, these processes are
mainly responsible for the highly diverse repertoire of antibodies found in the human body.
This variation is the basis of the existence of different antigen‐binding specificities and affinities
of immunoglobulins (Igs) [2, 9].
The story of antibodies can be dated back to 1890, with the first report detailing the presence
of antibodies and its function by Emil von Behring and Shibasaburo Kitasato. They used serum
from animals immunized against diphtheria for administration to other animals infected with
diphtheria and subsequently curing the infected animals [10, 11]. However, Paul Ehrlich in
1900 proposed the side‐chain theory based on his hypothesis that the binding ability of a
receptor is based on the side chains available for binding [12]. The side‐chain theory was then
supported by the ‘lock and key’ hypothesis by Emil Fischer that focused the hypothesis mainly
on enzyme functions [12]. The constant evolution and understanding of immunology has
helped open new avenues of antibody application and function.
Another major breakthrough in antibody technology development is the introduction of
hybridoma technology. Traditionally, antibody production for diagnostic applications
involved the use of animals. The immunization of animals with an immunogenic protein with
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and without an adjuvant would generally produce a collection of polyclonal antibodies [13].
A polyclonal pool of antibodies is defined as a set of heterogeneous antibodies targeting a
specific antigen at multiple epitopes. The ability to identify monospecific antibodies only came
about after Kohler and Milstein introduced the hybridoma technology in 1975. Hybridoma
technology allows for monoclonal antibodies (MAbs) to be produced by fusing myeloma cells
with antibody‐producing spleen cells to create a hybrid exhibiting both characteristics [11].
This resulted in the formation of an immortal cell line with characteristics from both the
spleenocytes and myeloma cells known as a hybridoma. The hybridomas are then screened
until a single clone is obtained and the production of it is up‐scaled. It is well known that
antibodies generated via this manner are likely to have high affinities due to the maturation
process that it underwent. Although successful, the process may be cumbersome and time
consuming as researchers have found it at times difficult to generate antibodies using this
method against toxic antigens, self‐antigens and sensitive antigens such as membrane proteins
or DNA. For all the benefits attributed to hybridoma technology, a major pitfall lies in the fact
that for every new antigen a new animal host is required for immunization. Thus, it is difficult
to predict or predefine the genetic information and epitope of the clone [11, 14]. This increas‐
es the difficulties, cost and time required to make antibodies, making it not the idle solution
for antibody production [14].
This brought about a string of alternative methods for antibody production. The turn of the
century saw the booming of molecular biology due to the success of recombinant DNA
technology. Researchers were hard at work to develop the next alternative method for
monoclonal antibody generation. This brought about various methods including phage
display and other multiple display methods such as yeast display, ribosome display and
mammalian cell display methods [14]. In addition, the use of transgenic animals was also
introduced mainly with the xeno‐mouse technology [11, 13, 14]. Even so, phage display is the
preferred choice for recombinant antibody (rAb) production in most laboratories. Phage
display allows for a faster and cost‐effective solution towards antibody generation using Ff
filamentous phage. In general, rAb production involves several steps including the genera‐
tion of an antibody library, selection and enrichment of phage‐displaying antibodies against
specific antigens through the panning process, screening of monospecific antibodies and
recombinant production of the antibodies via expression systems [15]. As phage‐derived rAb
may suffer from lower affinities, an additional stage of affinity maturation may be intro‐
duced to improve the antibodies produced. A major advantage to the use of phage display for
rAb generation in contrast to conventional animal‐derived methods is clearly the omission of
animal use in the process. Another advantage of phage display is the lower downtime required
for antibody production in between antigens. Conventional methods require immunization
that may take up to weeks if not months to yield sufficient immune response for antibody
production. This makes phage display rather efficient in the long term for antibody produc‐
tion process. However, one must acknowledge that phage‐derived antibodies suffer from
lower affinity when compared to conventional antibodies. This is due to the absence of affinity
maturation in phage‐derived antibodies as animal‐derived antibodies are produced post
maturation.
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This chapter highlights monoclonal antibody development for diagnostic applications via
phage display technology. This includes the different types of antibody libraries associated
with antibody phage display. The chapter also highlights the different methods used to isolate
antibodies against target antigens. The application of recombinant antibodies in different
diagnostic platforms is also discussed briefly.
1.1. Phage display section
Phage display makes use of the natural replication cycle of bacteriophages to fuse a specific
peptide or protein with the coat protein on the surface of the filamentous phage particles for
selection. This design allows the presentation of a predefined foreign phenotype on the phage
surface with the genotype being retrievable in the phage. This allowed a physical linkage
between the phenotypic characteristics with the genotypic information to be established [11,
16–22].
There are two main methods for the display mechanism on phage. The first is with the use of
a phage vector system, which allows the expression of coat protein III (pIII) to the foreign
protein, in this case the antibodies are driven by the natural phage promoter [23, 24]. Additional
helper phages are not required for phage packaging with phage vector systems. Unlike the
phage vectors, the expression of the antibody‐pIII protein by phagemid systems requires an
artificial promoter such as the lac promoter. In addition, phagemid systems also require helper
phage for phage packaging. As phagemid vectors do not carry the phage genome, complete
phage packaging can only be done with the presence of the helper phage that carries the genetic
information for the other proteins required for phage packaging. Therefore, a competition
between wild‐type pIII with the mutant pIII will occur. This difference in design of both phage
and phagemid vectors also contributes to the display efficiency as phage systems are able to
provide a multivalent display of the antibodies on pIII, whereas phagemid systems only allow
monovalent display.
The isolation of antibody‐presenting phages post binding with a target antigen allows simple
identification of the clones by standard sequencing. Therefore, this approach has been utilized
to introduce a collection of different antibody sequences into the phagemid vector to pro‐
duce a collection of varying clones known as an antibody library [25]. The generation of
antibody libraries will bring together a different set of considerations that is outlined in the
following section.
2. Antibody library
For antibody isolation with phage display technology, a collection of antibodies has to be first
made available. This involves the initial investment to generate a library of antibody clones to
be presented on the surface of bacteriophages. The choice of library to be generated is rather
dependent on its application, which would influence the subsequent decision‐making process.
This is because the type of library required would determine the source required and the
minimum library size required ranging from 106 to 1010 [26]. In general, there are four main
types of antibody libraries, namely naïve, immunized, synthetic and semi‐synthetic library.
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Naïve and synthetic antibodies are known as ‘single‐pot’ libraries, which can be screened
against any antigen [22, 26]. Figure 1 shows the overall summary of all the libraries and their
differences. However, each different library has its own particular characteristic that makes it
preferred for certain applications. The application of phage display for antibody generation is
not confined only to human antibodies but can also be applied to animal‐derived antibodies.
Figure 1. Types of antibody library design.
2.1. Naïve antibody library
Naïve antibody libraries are by definition a collection of antibody genes that are naïve in
nature. In other words, the V‐gene repertoire originates from IgM isotype of unimmunized or
healthy donors [21]. The main characteristic of a naïve library is the unbiased nature of the
repertoire. The antibody repertoire of healthy donors would mean no prior exposure or
infection of the donors to any form of infection that could skew the immune response. As
antibody production by the immune system is a direct response to the exposure of the
individual to any pathogen, it is necessary for naïve libraries to obtain its repertoire from truly
healthy donors.
The main advantage of a naïve or single‐pot library is its large repertoire [22] for monoclo‐
nal antibody identification against numerous targets such as self, non‐immunogenic or toxic
substances. A technical bottleneck associated with naïve libraries is the sheer number of donors
required as well as the number of theoretical diversity required. This would involve a large
number of ligation and transformation experiments to achieve such numbers. A common
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problem of naïve libraries is the number of unknown and uncontrollable contents, such as the
presence of memory cells of past infections that might influence the true nature of the naïve
repertoire due to the huge naïve repertoire [27]. Another issue common to naïve libraries is
the isolation of antibodies with varying degrees of affinities. It is common to obtain antibod‐
ies of modest affinities using naïve libraries, as the repertoire would have not undergone
affinity maturation processes as opposed to hybridoma‐derived or immunized library‐derived
antibodies.
The adaptation of naïve antibody libraries for diagnostic applications is not a new concept
with several antibodies successfully being isolated for various diagnostic targets. Naïve
libraries are useful for diagnostic as it can be used for selection against haptens, foreign and
self‐antigens. The ErBb2 protein, which is a tumour marker expressed by breast tumour, was
selected against a naïve antibody library to obtain antibodies for immunoassay applications
[28, 29]. Table 1 summarizes the application of naïve antibody libraries to generate antibod‐
ies against a variety of antigens for diagnostic purpose.
Library Library
size
Source Format  Target Ref
Tu, 2016 2 × 107 Alpaca  sdAb
(VHH)
Listeria monocytogenes (LM) [27]
Yan, 2015 6.86 × 1011  Camel  sdAbs Human procalcitonin (PCT) [28]
Ying, 2014 1 × 1012 Human  Fabs Receptor‐binding domain of the
MERS‐CoV spike glycoprotein
[29]
Zhang, 2013 n/a Human Fabs TES1 domain of the oncogenic LMP1  [30]
Boruah, 2013 n/a Ilama dsAbs Glycoprotein of the Rabies virus
(RABV)
[31]
Kirsch, 2008 (human naïve
HAL4/7 antibody gene library)
5 × 109 Human scFv Alphavirus species (virus) [32]
Velappan, 2007 n/a Human scFv Sin Nombre Virus nucleocapsid
protein (SNV‐N)
[33]
Jiao, 2005 2 × 109 Human Fabs Receptor tyrosine kinase Met [34]
McElhiney, 2000 1.47 × 108 Human scFv Microcystins [35]
Sheets, 1998 6.7 x 109 Human scFv ErbB2 protein, Malaria (rPfHRP2) [25, 36]
Table 1. Examples of naïve antibody libraries applied for diagnostic applications.
2.2. Synthetic and semi‐synthetic antibody library
The antibody‐binding region is located at the three complementarity‐determining regions
(CDRs) of the variable region in both the light chain and heavy chain. The gene sequences
along the CDR are highly heterogeneous as a consequences of gene diversification such as
V(D)J gene recombination, class switching and somatic hypermutation. The randomization in
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the CDR is responsible for the varying affinities as well as specificity to all target antigens.
DNA technology advancement encourages synthetic antibody design and synthesis at a
reasonable cost in laboratory with the help of structural bioinformatics. This is because the
prediction of antibody‐antigen interaction can be done after considering the antibody
structural constraints and preference.
It is with this information that antibody engineers are now able to design, improve and
generate customized frameworks for antibody production. The ability to synthesize specific
gene sequences and codons has made it possible to introduce randomization at the CDR. In
general, CDR3 are found to be the region with the highest diversification other than CDR1 and
CDR2 [30]. In addition to gene randomization, antibody‐binding site was altered by insert‐
ing preferential amino acids that can also be used to introduce specific criteria to the anti‐
body‐binding sites. Another key factor is the CDR length that can also be predefined by the
user.
In the context of synthetic antibody libraries, the natural immune maturation and somatic
hypermutation process can be elevated to generate similar quality antibodies. To construct a
synthetic library, the unarranged and randomized V‐gene segments are synthetically assem‐
bled ex vivo normally by polymerase chain reaction (PCR). However, customization can be
done on the genetic sequence, local variability and overall diversity for synthetic libraries
unlike naïve libraries. Even specific codon usage can be applied to suit the needs of the user.
Modifications to the framework can be carried out to improve features such as solubility and
heat stability [31]. The main criterion for synthetic libraries to be beneficial is the theoretical
diversity of the library. As the repertoire is largely naïve, the potential combinations generat‐
ed by synthetic methods are able to rival the process carried out naturally with the large library
size. However, the sheer size of the library diversity makes it difficult to re‐culture without
eventual loss of diversity. Even so, the antibodies enriched from synthetic libraries showed
comparable affinities to those derived naturally [32]. Another major bottleneck associated with
the use of synthetic libraries is the cost of generating a synthetic library. Even so, the turn of
events in genetic engineering over the past few years has seen the cost for oligonucleotide
synthesis reduced tremendously. Therefore, now it is a plausible solution for most laborato‐
ries to generate their own version of a synthetic antibody library.
A key subset of synthetic libraries is the production of semi‐synthetic libraries. The first semi‐
synthetic library was reported in 1992, in which rearrangement of 49 human VH gene segments
with five to eight residues of synthetic CDR was carried out to yield a semi‐synthetic single‐
chain fragment variable (scFv) library [33]. The key difference between semi‐ and fully
synthetic libraries is the source of the diversity. In semi‐synthetic libraries, the diversity is
largely obtained from natural sources whereby the genes encoding the CDR are isolated. These
CDR genes are then inserted to a fixed framework sequence, which encodes the antibody
backbone [27, 34]. The diversity is still natural, taking advantage of the maturation processes
of antibodies in vivo. The application of synthetic antibodies to develop antibodies for
diagnostic applications has allowed the generation of antibodies against various antigens of
diagnostic value.
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This is evident with approximately three billion clones in the ETH‐2‐Gold library that were
used against a wide range of recombinant antigens, such as extracellular glycoprotein of
tenascin‐C (TNC) [35]. Other versions have been reported such as the Tomlinson I library
with 18 amino acid side‐chain diversity on the CDR, and the Griffin library [36] was con‐
structed by using six diverse synthetic CDR3 regions [37]. The main difference between
Tomlinson I and J libraries is the choice of randomization used before clone into pIT2 phagemid
system. The Tomlinson I library uses the DVT degeneracy to introduce diversity at the CDR.
The Tomlinson J library makes use of the NNK degeneracy in the CDR design. Nucleotide
degeneracy is commonly used to introduce mutations in the codon at the CDR regions that
are responsible for antigen‐binding specificity and affinity. DVT and NNK degeneracy are
generic codons abiding a specific formula for base usage. The base usage of each degeneracy
is as follows: D is 33% G/33% A/33% T; V is 33% G/33% A/33% C; N is any nucleic acid and K
is 50% G/50% T. When the degeneracy is translated as a codon, it will yield multiple combi‐
nations of amino acids to increase the diversity of the gene. The application of different
degenerate codons also allows the application of different groups of amino acids in the CDR
design. The antibodies isolated from these libraries could then be used as a diagnostic tool [37,
38].
The HuCAL library from Morphosys is a famous fully synthetic antibody library with
predefined randomized frameworks [39]. The different versions of the HuCAL libraries,
namely HuCAL Gold and HuCAL Platinum, were generated with six trinucleotide‐
randomized CDRs [40, 41], whereas HuCAL and HuCAL Gold libraries were made with seven
VH, four VK and three Vλ germline families. This allows the generation of 49 framework
combination of the VH‐VL [42]. Structural diversity of the CDR was introduced by
randomization of CDR1, CDR2 and CDR3 [39]. Another version of the HuCAL library is the
HuCAL Platinum that consists of seven VH, three VK and three Vλ framework sequences.
HuCAL Platinum was designed without the use of VH4 and VK4 as they are found to be
rare [43]. The HuCAL libraries have been used also for antibody generation for the diagnosis
of bovine insulin [39, 40, 42]. Table 2 shows a list of some known fully-synthetic and semi-
synthetic libraries used for diagnostic applications.
Library Type Diversity generation  Format Target Ref
Synthetic phage
display nanobody
(Nb) library 
Synthetic Degenerate codon NNK scAbs
(VHH) 
Human prealbumin (PA) and
neutrophil gelatinase‐associated
lipocalin (NGAL)
[50]
Synthetic Synthetic – scFv Coronary artery disease (CAD) [51]
ETH‐2‐Gold
library 
Synthetic – scFv Extracellular glycoprotein C‐
domain of tenascin‐C (TNC)
[42]
Ylanthia Library Synthetic Fixed VH/VL framework
pairs selected on biophysical
characteristics 
Fab Recombinant human (rh) ErbB4,
rhFZD4/Fc, rhTNFalpha, M‐CSF,
eGFP
[49, 52]
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Library Type Diversity generation  Format Target Ref
HuCAL Gold Synthetic 7 VH, 4 VK and 3 Vλ
germline family
scFv, Fab IL18R‐Fc,  ‐Gal, Est‐BSA [46, 48]
HuCAL Platinum Synthetic 7 VH, 3 VK and 3 Vλ
framework
Fab Human TRAIL R2/Fc and rhIL‐
2Rαalpha;/Fc fusion protein
[47]
Tomlinson I
Library
Synthetic DVT side chain scFv Microcystins, ferritin, SARS‐
associated corona virus
[35, 51,
53]
Griffin Library Semi‐
synthetic
– scFv Microcystins [43, 44]
Tomlinson J
Library
Semi‐
synthetic
NNK side chain scFv SARS‐associated corona virus [53]
Table 2. A list of fully‐synthetic and semi‐synthetic libraries and application in diagnostics.
2.3. Immunized library
The immunized library repertoire originates from V‐gene of immunized donors [27] or disease‐
infected donors. In immunized libraries, the immunized repertoire would be specific for one
antigen or a collection of antigens specific for a particular disease. This limits the use of the
libraries when compared to naïve and synthetic libraries. Even so, the V‐genes are collected
from donors that have been exposed to the target antigen allowing isolation of higher‐affinity
antibodies using such libraries. These antibody libraries mainly produce antibodies of good
affinities with high clonal diversity due to in vivo somatic hypermutation that contributes
towards affinity maturation. This would influence the library diversity in a way that the final
library size required does not necessarily need to be as high as naïve libraries [26]. This is useful
to study disease immune responses, vaccination strategies and human immunity. The major
setback to such libraries is the need to generate a new library to study every different
disease [22, 26, 27].
Several different libraries have been developed for various diseases such as hepatitis B [44]
and those listed in Table 3. These libraries contain a plethora of useful antibodies that are
specific to the disease making it a valuable asset for infectious diseases. The generation of
immunized libraries is not restricted to humans but can also be carried out in animals such as
mice. Immunization of mice with the target antigen would likely yield a library of clones
against the specific target protein. Although this may not differ much from the conventional
hybridoma technology, however, conversion to a recombinant version would allow easy up‐
scaling for production and also for modification.
Library Source Format Target for diagnosis Ref
Gong, 2015 Camel sdAbs (VHH) H7N2 virus [61]
Prantner, 2015 Human sdAbs Mesothelin cancer biomarker [62]
Zhou, 2015 Chicken scFv Bursal disease virus (VP2 protein) [63]
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Library Source Format Target for diagnosis Ref
Hosking, 2015 Buffalo scFv Schistosome infection [64]
Zhou, 2015 Rainbow trout scFv Viral haemorrhagic septicaemia, VHS (viral
haemorrhagic septicaemia virus, VHSV)
[65]
Unger, 2015 Ilamas/camelid scAbs (VHH) Clostridium difficile toxin (CDT) [66]
Li, 2015 Camel scAbs (VHH) Coronary artery disease, CAD (Apolipoprotein B‐100) [67]
Sabir, 2014 Camel sdAbs (VHH) Tuberculosis (TB) [68]
Shahi, 2014 Camel scAbs (VHH) Botulinum neurotoxin E (BoNT/E) [69]
Mohammadzadeh, 2014 Mice scFv HIV‐1 capsid protein p24 [70]
Li, 2014 Chicken scFv Newcastle disease virus (NDV) [71]
Yang, 2014 Camel scAbs (VHH) Porcine circovirus type 2 (PCV2) [72]
Zhu, 2014 Camel scAbs (VHH) Influenza H3N2 [73]
Chiliza, 2008 Chicken scFv Malaria [74]
Cumming, 1998 Mice scFv Mycobacterium tuberculosis (65‐kDa Mtb antigen) [75]
Table 3. A list of immunized antibody libraries and application in diagnostics.
Immunized libraries have been used successfully in developing antibodies against diagnos‐
tic biomarkers. This can be seen with the application of this concept for epitopes of immuno‐
genic antigen, such as carcinoembryonic antigen (CEA) [32, 45]. Anti‐CEA antibodies can be
applied for targeting and to image colorectal tumours. This transcends the conventional
diagnostic platforms allowing in vivo cell staining or even with clinical imaging technologies.
Besides, immune Fab antibody libraries were used to isolate antibody clones against human
immunodeficiency virus type 1 (HIV‐1), respiratory syncytial virus (RSV) and herpes simplex
virus (HSV) [46]. Additionally, hepatitis A antibodies were isolated from hepatitis A im‐
mune library against CR236 via serodiagnostic immune adherence test (IA) or complement‐
fixation (CF) test [47]. Diagnosis of heparin‐induced immune thrombocytopenia (HIT) was
made possible by using HIT antibodies from immune libraries. This is crucial as patients who
have been diagnosed with HIT are required to stop heparin and start using alternate anticoa‐
gulant for treatment [48, 49]. Diagnosis of anthrax was done via detection against antigen
Bacillus anthracis spores with immunized scFv antibody phage display library [50].
3. Selection and screening of antibody libraries
Panning is an in vitro selection method that functions to isolate antibody fragments based on
their affinity towards the antigen from a diverse collection of clones. This approach is common
for antibody development for diagnostics and therapeutic application [51, 52]. Before selection
of antibodies can be carried out, the antibody libraries must be developed first. The construct‐
ed library must then be packaged as fusion protein on bacteriophage particles. The basic
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principle involves accessibility of phage‐presenting antibodies to bind to a target antigen based
on affinity.
Figure 2. Antibody selection bio‐panning protocol.
In this respect, (Figure 2) shows that the target antigen must first be immobilized on solid
surfaces such as nitrocellulose, magnetic beads, column matrices or plastic surfaces in the form
of polystyrene tube or 96‐well microtitre plates [22]. In fact, the major difference among all the
panning selection strategies is the immobilization surface where antigens are coated on. Other
than this, parameters such as washing, elution and enrichment steps can be optimized for a
successful selection process. As for evaluation, polyclonal and monoclonal antibody phage
enzyme‐linked immunosorbent assay (ELISA) is usually used to determine the presence of a
positive clone after panning [53].
3.1. Conventional panning strategy
To date, there have been a number of different panning strategies reported for the isolation of
MAbs against various antigens. Traditionally, the favoured method for most researchers is to
immobilize or coat antigens on solid supports such as polystyrene immunotube and polystyr‐
ene immunoplate [53].
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The attachment of antigen to the polystyrene surface can either be direct using surface‐treated
plates or by using intermediate capture mechanisms. This includes streptavidin‐coated plates
to capture biotinylated ligands (protein or peptide). The biotin‐streptavidin mechanism is
useful to avoid epitope disconformation during antigen immobilization on a plastic surface
[54]. After the immobilization of antigen, phage‐displayed libraries are incubated with the
bound antigens for affinity capture. This was then continued with the washing of unbound
phages before phage elution for rescue. Then, the eluted phage was subjected to amplifica‐
tion and precipitation steps for the following panning round until a positive clone is ob‐
tained [55]. Here, the wash step can be modified to introduce different degrees of stringency
to specify certain characteristics required for the antibodies. This way, customization of the
strategy helps to determine the final output characteristics.
3.2. High‐throughput panning strategies
To increase the screening effectiveness, streptavidin magnetic beads can be used to coat the
biotinylated antigens. A major advantage in using nanoparticles is the higher surface area to
volume ratio for the capture of higher amount of targets. Magnetic‐based panning allows
multiple antigen screening at the same time. A semi‐automated panning process includes
manipulation of magnetic beads by multi‐pin method, robotic arm or a robotic system during
the panning process to increase the panning efficiency [56]. The main concept of panning using
the semi‐automated process applies a similar concept of affinity‐based selection as the
conventional method. The incubation, wash and elution steps are carried out with automa‐
tion to improve reproducibility and accuracy. However, the phage rescue process is still carried
out offline by manual infection. Even so, the process still utilizes significant automation to
lower labour involvement and allows for high‐throughput screening to be carried out.
The concept of full automation refers to a pipeline process without the involvement of any
human, whereas semi‐automation requires human involvement at some point of the process
[53]. The main benefit that high‐throughput panning brings to the process is a higher efficien‐
cy in selection with minimum labour as all the parameters can be easily programmed for
repetitive steps. This also increases reproducibility of the incubation time, temperature,
washing and elution condition. This allows for easy handling of multiple targets at the same
time. Such protocols can help to reduce from 2 days to a single day for one selection cycle,
which means only a week is required for the entire panning process. This method is easily
automated with the use of magnetic particle processors such as the Kingfisher Flex system [56].
The next‐generation phage display allows differentiation of unselected and selected phage
after enrichment rounds [57] against a target antigen for both large combinatorial peptide and
antibody libraries through DNA sequence analysis of the phenotype‐bearing phage [51]. There
are some similarities of this platform with conventional phage panning, where both includes
laborious colony picking and functional ligand screening. The sheer number of clones to be
analysed is easily overcome by the use of next‐generation sequencers (NGSs). This strategy is
cost‐effective, fast and less labour intensive as compared to conventional phage display
selection. Moreover, this technology improves the overall accuracy for large quantification. In
terms of coverage, DNA deep sequencing through NGS offers a high coverage for full
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repertoire of ligand particles. In short, high‐throughput DNA sequencing through NGS
method is cost‐effective, provides higher accuracy and high coverage for large quantifica‐
tion especially for library screening [57].
Another method utilizing the mass spectrometry immunoassay (MSIA™) system was
introduced where the separation of antibodies and antigen for mass spectrometry (MS)
analysis is done via affinity. Previously, the MSIA™ method is an immune affinity method
used in protein analyte purification for MS detection purposes. The MSIA™ tip was success‐
fully used as a solid phase to carry out semi‐automated panning for antibody enrichment. The
MSIA™ tips that contain streptavidin that are covalently linked to a porous monolithic solid
support will function as the capture molecule. The streptavidin capture molecules are best
known for the easy capture of biotinylated target through biotin‐streptavidin interaction. The
MSIA™ tip method only requires the use of a standard electronic multichannel pipettor and
an adjustable pipette stand. This method is also cost‐effective for phage display panning as it
does not require investments on instrumentation. However, the method can also be incorpo‐
rated to larger pipetting instruments for antibody panning also. The panning protocol uses the
similar concepts as conventional panning that includes incubation, washing and final elution.
Then, bound phages are then amplified and used in the following panning rounds to obtain
clonal enrichment. This method was reported to successfully identify antibodies against the
hemolysin E antigen of Salmonella typhi [58]. In short, this method is also an attractive
alternative for high‐throughput screening.
3.3. Cell panning
Cell panning is an innovative screening method using whole fixed or live cells, tissue section
or live animals expressing the antigen of interest for panning [22]. In other words, whole live
cells serve as an antigen carrier to screen phage antibodies [59, 60]. All the selection methods
mentioned were panned against purified antigens, but whole cell antigen is used in whole cell
panning. This panning strategy is usually an alternative method for complex and difficult
antigens which cannot be purified with similar properties, for example, cell surface receptor
or antigen [60] is only functional when retained in lipid bilayers [59]. There are several
parameters to consider when carrying out cell panning such as (1) quality of antibody
library, (2) display manner, (3) antigen concentration and (4) cell‐surface antigen density. This
is to ensure the success of the panning process.
4. Antibody formats
Antibodies are normally identified in a Y‐shape configuration. The variability is mainly due
to the V‐region (two arms of Y‐end) as this is where the antigens bind [61]. Thus, smaller
versions of antibody formats have been developed to take advantage of the binding specific‐
ities of the V‐region. Due to advancement in recombinant DNA technology, a number of new
antibody formats such as domain antibodies, single‐chain fragment variable, tandem scFv,
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diabody, tetrabody, minibody and single‐chain fragment antigen binding (scFab) have been
introduced (Figure 3).
Figure 3. Antibody fragment design. (A) Full antibody; (B) fragment antibody binding (Fab); (C) single‐chain fragment
variable (scFv); and (D) single‐domain antibody (sdAbs).
A main consideration of antibody formats is the size; smaller fragments have an advantage
that they are able to retain the antigen‐binding specificity and can be produced economically
[26, 62]. This is important for application in diagnostics, as this will in turn contribute to
lowering the production cost during manufacturing. The main consideration for any anti‐
body to be used on a diagnostic platform is mainly the specificity and affinity of the anti‐
body against the target antigen. These two characteristics are not lost with the use of smaller
fragments albeit there will be no avidity effect with the monomeric smaller fragments.
Both scFv and Fab formats are commonly used in research and industrial applications, and
are the preferred formats for presentation on phage [16, 20, 34, 62, 63]. This is because the
expression of complete IgG is not suitable for Escherichia coli as the large size and post‐
translational modifications available are not designed for bacteria [64]. In the context of
antibody formats for application in phage display, the smaller‐sized formats are preferred due
to the ease of expression and presentation efficiency. Larger native structures may not be
tolerated well by the bacterial host required for the packaging of new phage particles. The
following section will mainly discuss the antibody formats commonly used in phage display.
This includes the domain antibodies, single‐chain fragment variable and fragment antigen
binding, which are truncated versions of the full immunoglobulin.
4.1. Domain antibody (dAb)
Domain antibodies are small (11–15 kDa) and consist only of either the VH or the VL do‐
main [34]. Thus, they will only have three out of a possible six CDR from a full variable region
consisting of both VH and VL. It was found that single‐domain antibodies (sdAbs) are able to
provide better stability as well as solubility when specific families such as the VH3 frame‐
work are used. The stability of the human VH domain antibody can be further enhanced by
extending the length of CDRH3 loop [65], much like the hypervariable region of camelid VHH
that are longer than the human VH. According to Ponsel and Neugebauer [34], camelid and
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cartilage fish's single‐domain antibodies are more stable, with a high resistance towards
aggregation and temperature due to the framework sequence [34, 66].
Domain antibodies can also penetrate tissue efficiently as compared to full‐length IgG due to
their smaller size. VHHs are commonly used as detection units on biosensor or immune‐
adsorbent to identify the presence of lysozyme, carbonic anhydrase, alpha‐amylase [67], beta‐
lactamase or even act as a cancer‐imaging agent. It was also used to detect the surface antigen
of different hepatitis serotypes [66]. In addition, single‐domain antibody is used due to an
easier production system when compared to conventional antibodies because of the size and
folding [56, 68]. As domain antibodies are devoid of any quaternary structure, production and
stability of domain antibodies allows it to be used at extreme conditions. This provides great
benefit for diagnostics, as the improved heat stability would allow easy transportation of
antibodies without cold chain. This is especially beneficial for diagnostic kit development for
in‐field diagnosis of infectious diseases in areas with limited resources.
4.2. Single‐chain antibody variable fragments of ∼27 kDa
Single‐chain antibody variable fragment is made up of VL and VH domain with a glycine‐
serine flexible linker in between to hold the domain in proximity to form the binding cavity
upon folding [3]. In addition, GS linkers are known to improve the folding, flexibility and
stability of the single‐chain fragment variable as compared to proline‐rich linker. This is
because pro‐rich sequence exhibits rigid and stiff conformation due to the absence of hydro‐
gen at the amine, which forms hydrogen bonds with other amino acids [69]. Therefore, the
scFv fragments are designed with six CDRs, thus increasing the diversity and repertoire of the
antibodies. The scFv has been shown to bind to a variety of antigens, such as hapten, protein,
carbohydrate, receptor, tumour antigen and viruses [63]. Moreover, small scFvs are easily
folded and producible in E. coli for diagnostic applications too [3, 63, 64, 70].
As a linker joins the VH and VL domain physically, the single polypeptide composition helps
to facilitate the production and folding in E. coli that allows for efficient presentation of
antibody repertoire on phage surface [70, 71] due to better expression in E. coli [14, 71]. Thus,
many libraries generated use the scFv fragment as the preferred format for selection [64, 72].
The scFv format has been used in whole blood agglutination assay for rapid diagnostic test for
HIV‐1 [71]. The scFv fragment was detected by tags in ELISA besides fusing with reporter
enzyme to act as secondary antibody [73].
4.3. Fragment antibody‐binding fragments of ∼57 kDa
As a comparison to scFv, Fab fragments are composed of the VH, CH1 and entire VL frag‐
ment held together by interchain disulphide bonds. The Fab fragments have a tendency to
form dimers which could cause problems with binding and affinity as it exerts the avidity
effect [13]. In vitro, Fab expression vector is more complex than the scFv system as it consists
of two separate polypeptide chains linked by the formation of a disulphide bridge. Thus, it is
important to ensure a balanced expression of both antibody chains in order to allow good
presentation of Fab on phage.
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There are several designs used for Fab presentation that includes either the monocistronic or
the bicistronic arrangement of antibody. The gene arrangement of a Fab fragment for phage
display requires fusion of either VL or VH to the phage pIII coat protein. The production of
the accompanying chain will be carried out simultaneously as an independent protein allowing
it to locate each other at the periplasmic cavity to form disulphide bonds between them for
proper presentation. This challenge is overcome by alternative approaches using molecular
chaperones to improve the presentation of full Fab fragments during phage display and
protein expression [74].
In diagnostic applications, Fab‐peptide epitope and Fab‐Fab bifunctional reagent were used
to detect the HIV‐1, HIV‐2 and hepatitis B surface antigen, which were known as antibody‐
based reagent [71] in agglutination assays. Table 4 shows the broad application of different
antibody formats for diagnostic applications. There is no actual best format for diagnostics but
is mainly subjected to the preference of the users and the diagnostic platform set‐up.
Antibody fragment format Source Antigen Disease Ref
Single Domain antibody
(sdAb)
Camel Prostate‐specific antigen (PSA) Prostate cancer [98]
Semi‐synthetic Mycobacterium tuberculosis (MTb) α‐
crystalline
Mycobacterium
tuberculosis 
[99]
Ilama Marburg virus variants Haemorrhagic fever [100]
Human Protein C3a, cancer antigen,
carcinoembryonic antigen, MUC
family glycoproteins, autoantibodies,
sialyl‐LewisX and cytokines 
Breast cancer [101]
Alpaca (VHH) Listeria monocytogens (LM) Food‐borne pathogens [27]
Camel (VHH) H7N2 virus Avian influenza virus
subtype H7N2
[61]
Single‐chain fragment
antibody (scFv)
Mice Bacillus anthracis spores (exosporium) Anthrax [60]
– Domoic acid Amnesic shellfish
poisoning (ASP)
[102]
Mouse Clostridium difficile toxin B C. difficile infection, cause
of nosocomial diarrhoea
[103]
Mice Prostate‐specific membrane antigen
(PSMA)
Prostate cancer [104]
Fragment antibody binding
(Fab)
Human Anti‐carcinoembryonic antigen (CEA) Colorectal carcinoma [105]
Mouse prostate‐specific antigen (PSA) Prostate cancer [106]
Human Hepatitis B surface antigen (HBsAg) Hepatitis B [54]
Table 4. Application of antibody fragment as diagnostic probe.
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5. Application of recombinant antibodies in rapid diagnostics
Recombinant antibodies are used in diagnostics due to its binding specificity and affinity.
There are many platforms, such as lateral‐flow assay (LFA), ELISA and cell imaging availa‐
ble in the market today, which are rapid and accurate in identifying the target antigens found
in sample. Most of the platforms make use of either the antigen‐capture assay or the anti‐
body‐capture assay to diagnose the presence of certain diseases [75].
5.1. Lateral‐flow dipstick assay
Lateral‐flow assay or immunochromatography assays are normally found as a test strips with
the most common being the pregnancy test strip. The theory behind lateral‐flow assay is based
on the capillary action that occurs in the nitrocellulose membrane to migrate molecules along
the membrane to cause a reaction and detect target antigen [75, 76]. This is because the presence
of antigens in the sample matrix against a specific antibody reflects the onset of certain disease
and treatment should be carried out immediately. (Figure 4) shows the actual design,
polyclona antibodies against the target antigen were conjugated with gold nanoparticles and
are deposited on the membrane. The migration of the sample when mixed with the antibody‐
coated particles will allow the particles to flow along the membrane until it is captured by a
secondary antibody that is permanently fixed along the membrane as a line. Therefore, the
presence of the antigen will be reported by the appearance of a band on the dipstick that
represents the concentration of the gold nanoparticles on the target line.
Figure 4. Lateral‐flow dipstick assay design.
The conventional design of the lateral‐flow strips will show a single control line and another
test line. The control line indicates the control assay to show that the lateral‐flow system is in
order. The working assay requires buffer to improve the performance as well as the compat‐
ibility with other components used in assay. There are two formats used in LFAs, sandwich
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and competitive format [77]. In short, dipstick assay is sensitive enough to detect the antigen
constituent within 10 min besides the simple usage that does not require professional
personnel to carry out the test. The conjugation of recombinant antibodies to gold nanoparti‐
cles is essential for the generation of lateral‐flow assays. The ability to produce recombinant
antibodies easily using bacterial expression systems would facilitate rapid kit production at a
lower cost.
5.2. Microfluidic platform
Microfluidics makes use of the movement of small amounts of fluid along a small diameter
channel. Microfluidics was vastly applied due to the small sample volume needed for fast and
precise result. The microfluidic platform is highly sensitive, efficient and portable [78].
Recent developments in microfluidic technology including on‐chip detection and imaging, on‐
chip flow cytometry, on‐chip immunoassay and nanosensor for point of care (POC) diagnos‐
tic application [79] help to overcome conventional ELISA's limitation for immunoassay‐based
diagnosis; micro‐ELISA systems have been proposed for sensitive and rapid diagnostics using
a fluidic chamber. This modified ELISA platform uses a microfluidic platform that reduces the
amount of sample required by 10 times (<10 µL), 20 times faster analysis (<20 min) with a
higher sensitivity range (Um–pM) as compared to conventional ELISA [79, 80]. Rapid
diagnosis is the most important selling point for biomarkers such as protein, carbohydrate,
lipid, metabolites, genomic DNA and RNA by using immunoassay due to the obvious
advantage in disease management.
To improve the quantitative result, fluid‐handling components and data acquisition soft‐
ware were used. In addition, microfluidic kits are integrated with electrical, optical and
mechanical transducer to improve the platform [79, 80]. Other than that, the development of
on‐chip diffusion assay allows the measurement of small molecules within the microfluidic
channels. This is done by detection of the labelled probe by antibodies against the probe itself.
This study also proves that microfluidic diffusion is suitable for blood sample analysis [81].
There have been other versions of assays utilizing recombinant antibodies in fluidic plat‐
forms such as malaria detection with on‐card dry reagent storage of microfluidic immunoas‐
say from blood samples [79].
5.3. Enzyme‐linked immunosorbent assay
The ELISA platform takes advantage of the specific interaction between antibody and antigens
to allow a capture base for detection. The method requires a series of incubation and wash
steps, which can be time consuming and tedious. Thus, antigens are first coated on a microti‐
tre plate and then blocked overnight before incubation with antibodies. To detect binding
between antigen and antibody, bio‐conjugate and chemical‐conjugate proteins coupled with
reporter enzymes such as horseradish peroxidase (HRP) or alkaline phosphatase (AP) are used.
Lastly, 2,2’‐azino‐bis(3‐ethylbenzothiazoline‐6‐sulphonic acid) (ABTS) is used as a colour
indicator for successful binding between antigen and antibody. However, the conventional
ELISA approach has setbacks such as long assay time, large amount of expensive antibodies,
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chemicals, plastic ware and liquid‐handling platforms. This process although straightfor‐
ward may still require professional training in order to minimize any false‐positive result and
ensure reproducibility [82].
5.4. Nanoparticles, silica, polystyrene and latex agglutination test (LAT)
The advent of nanotechnology has brought about the introduction of nanosized particles and
with it a series of new diagnostic platforms. There are many nanoparticles that have been used
for diagnostic platforms. This includes gold nanoparticles (AuNPs) [83–86], carbon nano‐
tubes and carbon nanoparticles (CNPs) [87]. The chemical property of these nanoparticles has
allowed the expansion of the diagnostic platforms from simple colorimetric assays to the
introduction of electrical signal, fluorescence and even phase transition readouts [83–85].
Although the use of AuNPs is associated with its application in lateral‐flow dipstick assay as
the immobilization surface for DNA, antibodies and proteins for the line development, it has
also been used independent of the lateral flow. An assay was developed using AuNPs with
influenza‐specific antibodies acting as labels to detect influenza virus. This will result in the
AuNPs probe aggregating and causing a readout in dynamic light‐scattering (DLS) spectro‐
scopy. Thus, the detection of AuNP aggregation was analysed using the DLS to determine the
concentration of virus present. This method monitors the size change of aggregated nanopar‐
ticles and not change colour. However, the DLS approach is more suitable in detecting larger
viruses with multiple epitopes [88].
The latex antigen detection or latex immunoagglutination test established in 1959 makes use
of protein‐conjugated latex microspheres to magnify the antigen‐antibody interaction [89].
This LAT assay is fast and simple to use for the diagnosis of circulating antigens in patients
with systemic infection because latex is sensitized with the serum of an immune donor [90].
The latex complexes will agglutinate if the target antigen is present [91]. The LAT platform has
been used for the diagnosis of systemic candidiasis [90, 91], visceral leishmaniasis [89], invasive
pulmonary aspergillosis [92], Helicobacter pylori infection [93] and Meningococcal meningitis [94].
The diagnostic test can be done using blood, cerebrospinal fluid or other body fluids depend‐
ing on the design of the agglutination test.
5.5. Fusion with DNA technology—DNAzyme probe system, immuno‐PCR (IPCR),
immuno‐quadruplex priming amplification (IQPA), immuno‐rolling circle amplification
(IRCA)
Enzyme‐linked immunosorbent assay is an assay that uses the enzymatic reaction as a basis
of reporting. However, such assays sometimes suffer from a lack of sensitivity to detect low‐
dose drugs or biomarkers [95]. To overcome this issue, the fusion of DNA technology with
protein engineering has brought about newer reporter systems that can increase the sensitiv‐
ity of assays. This includes modified hybrid methods such as antigen‐DNAzyme, immuno‐
PCR, immuno‐QPA and immuno‐RCA.
The antigen‐DNAzyme‐based probe reporter system is a simple and rapid immuno‐based
assay that depends on the peroxidase activity as a reporter signal and the affinity of antigen‐
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antibody for binding. DNAzymes also known as deoxyribozyme, founded by Ronald Breaker
and Gerald Joyce in the year 1994, are catalytically active DNA molecules, which are able to
function mimicking enzymatic reactions [96]. G‐quadruplex (G‐quad) structures are formed
by guanine‐rich nucleic acids. The guanine‐rich sequence will form a guanine tetrad struc‐
ture with intra‐Hoogsteen hydrogen bonding. This will then allow two or more guanine tetrads
bind to form a G‐quad. The G‐quad structure is further stabilized by the presence of cations.
The complexation of G‐quad structures with a hemin will form a peroxidase mimicking
DNAzyme that catalyses the peroxidase‐mediated oxidation of ABTS [97, 98]. The main
difference of this antibody‐antigen detection assay is the use of G‐quad DNA structures in
association with hemin as a reporter system. The addition of hemin to a G‐quad structure will
allow the transfer of electrons from the guanine to hemin in the presence of peroxide to oxidize
the ABTS to form a green complex that is visible to the eye [98].
This assay design allows the fusion of the G‐quad to function as a DNAzyme to generate a
colorimetric readout as a reporter system for the rapid detection of small haptens such as
hormones or drug molecules [99]. Thus, DNAzyme can be conjugated with antibodies for
signal enhancement with the help of hemin and is suitable to be used as an immunoassay in
biodiagnostic platforms [98]. As the G‐quad sequence is made up of oligonucleotides, the
sensitivity of the assay can be greatly improved via external DNA amplification processes to
generate more G‐quad sequences for reaction with hemin.
Immuno‐quadruplex priming amplification is another hybrid method that couples both the
calorimetric DNAzyme detection with an effective DNA amplification for improved sensitiv‐
ity. IQPA is an immunoassay platform that generates G‐quad reporter molecules via an
isothermal quadruplex‐priming amplification process. The reporter G‐quad forming sequen‐
ces, which were amplified from isothermal QPA, allow QPA to fuse with an immunoassay
platform. In other words, we can avoid reporter conjugate enzyme in the immunoassay
platform. QPA employs a set of primer and enzyme to maintain the stringent condition for
target amplification to generate multiple copies of the G‐quad sequence at an isothermal
condition. Streptavidin can be sandwiched between the antigen and antibody DNA to form
the binding for IQPA to work. The hemin molecules are then used complex with the ampli‐
fied G‐quad structures to catalyse the colour change of ABTS in the presence of hydrogen
peroxide [100].
Immuno‐PCR is another hybrid immuno‐based assay that combines ELISA‐type ligand‐
binding assay (LBA) technologies with PCR amplification signal without the use of antibody‐
enzyme conjugates. As a replacement, antibody‐DNA conjugates were used whereby the DNA
marker is physically linked to the capture antibody and a polymerase chain reaction step is
introduced to generate copies of the DNA sequence. This allows improvements of 100–10,000‐
fold in limit of detection (LOD) as compared to conventional ELISA [95, 101]. Although the
LOD of IPCR is almost in line with the ligand‐binding assay, IPCR assay has been consid‐
ered as challenging. Thus, various modifications are required to increase its sensitivity. This
includes technical issues such as the availability of thermostable enzymes, high protein‐
binding capacity microplates and minimizing cross‐contamination by avoiding plate trans‐
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fer steps. IPCR has been reported in detecting human interleukin 6 (IL‐6) for neurological
disease [95].
A further enhancement includes the immuno‐RCA method that is another diagnostic plat‐
form, which utilizes DNA amplification steps to enhance the signal of immunoassay. This
method employs similar concepts to IPCR but the method of DNA amplification varies. As
IPCR utilizes the standard PCR amplification cycles, IRCA uses an isothermal amplification
method, which does not require a thermal cycler. This makes it more attractive as there is a
reduction of dependency on high‐end instrumentation. IRCA was used to develop assays in
detecting ovalbumin (OVA) allergens [102] and foot‐and‐mouth disease virus (FMDV) [103].
In IRCA, oligonucleotide primers are attached covalently to the antibody. However, DNA
circularization is required to allow binding of the DNA primer to work with DNA polymer‐
ase and nucleotides for amplification to start [104]. The detection sensitivity of IRCA ex‐
ceeds the conventional ELISA and microparticle formats. Thus, IRCA is a system that can allow
detection of specific antigens using antibodies at high sensitivity with a wide dynamic range
to detect a single molecule [104]. In short, DNA‐fusion technologies with recombinant
antibodies could potentially aid in the development of newer assays with improved sensitiv‐
ities.
6. Conclusion
Phage display technology is commonly used for recombinant antibody production. The ability
to produce antibodies via recombinant methods can help to improve the speed at which newer
antibodies are produced at a fraction of the conventional cost. The freedom associated with
recombinant antibodies would also allow the customization of antibodies for various down‐
stream applications in diagnostics. This is particularly important as the development of newer
technologies in sensing and reporting mechanisms, the flexibility of recombinant antibodies
towards modifications would allow the antibodies to evolve with the advancement of sensing
technologies. Therefore, phage display‐derived recombinant antibodies provide an impor‐
tant platform for antibody generation for current and future diagnostic applications.
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